Adlai Nortye (ANL) Research Hub

Adlai Nortye (ANL) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 10.58 USD (0.00%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -8.19, market cap 0.68B. This hub links to the full technical, earnings and options research available for ANL.

Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ

SectorHealthcare (Biotechnology)
ExchangeNASDAQ, US
Last close10.58 USD (0.00%)
52-week range8.54 USD – 16.95 USD
Trend regimeRange
14-day RSI32.7 (Bearish)
Trailing P/E-8.19
Market cap0.68B
Dividend yield0.00%
Next earnings2026-08-06

Available research for ANL

Earnings

ANL earnings date and last-quarter result: next report 2026-08-06, last quarter miss, P/E -8.19. Updated 2026-07-23.

Options: Covered Call

Covered Call on ANL: how it works, illustrative setup around the real 10.58 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Iron Condor

Iron Condor on ANL: how it works, illustrative setup around the real 10.58 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Protective Put

Protective Put on ANL: how it works, illustrative setup around the real 10.58 USD price, max profit/loss, breakeven and when to use it. Educational.

Technical

ANL technical analysis: range, last 10.58 USD, RSI 32.7, 52w range 8.54 USD–16.95 USD, real support/resistance. Updated 2026-10-26.

More on SniperIQ

Frequently asked questions

What sector is ANL in?

Adlai Nortye (ANL) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.

Is ANL in an uptrend or downtrend?

As of 2026-10-26, ANL is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.

What is ANL's trailing P/E ratio?

ANL's trailing P/E is -8.19, with a market cap of 0.68B. See the earnings research page for full valuation detail.

When does ANL next report earnings?

ANL is next scheduled to report earnings on 2026-08-06.